background
chikungunya
viru
chikv
recent
reemerg
arboviru
respons
massiv
outbreak
infect
indian
ocean
region
india
signific
potenti
spread
global
worldwid
distribut
mosquito
vector
chikv
induc
usual
selflimit
diseas
human
character
fever
arthralgia
myalgia
rash
howev
case
sever
chikv
infect
recent
describ
particularli
adult
underli
condit
neonat
born
virem
mother
method
human
polyval
immunoglobulin
purifi
plasma
sampl
obtain
donor
convalesc
phase
chikv
infect
prevent
cur
effect
immunoglobulin
investig
mous
model
chikv
infect
develop
result
chikv
immunoglobulin
contain
antichikv
antibodi
exhibit
high
vitro
neutral
activ
power
prophylact
therapeut
efficaci
chikv
infect
vivo
includ
neonat
conclus
administr
chikv
immunoglobulin
may
constitut
safe
efficaci
prevent
strategi
treatment
individu
expos
chikv
risk
sever
infect
neonat
born
virem
mother
adult
underli
condit
result
provid
proofofconcept
purifi
human
immunoglobulin
plasma
sampl
patient
convalesc
phase
emerg
infecti
diseas
neither
prevent
treatment
avail
chikungunya
mosquitoborn
diseas
caus
chikungunya
viru
chikv
member
togavirida
famili
alphaviru
genu
chikv
first
isol
epidem
polyarthralgia
tanzania
chikv
emerg
indian
ocean
region
caus
massiv
outbreak
infect
notabl
la
island
onethird
inhabit
infect
inhabit
develop
sever
diseas
die
vast
chikv
infect
outbreak
also
emerg
india
estim
million
case
note
chikv
signific
potenti
spread
global
worldwid
distribut
mosquito
vector
exemplifi
recent
emerg
itali
chikv
maintain
natur
uninterrupt
cycl
transmiss
mosquito
vector
far
unidentifi
vertebr
host
classic
chikv
infect
character
fever
polyarthralgia
myalgia
frequent
associ
rash
joint
symptom
often
debilit
usual
resolv
within
day
week
relaps
arthralgia
frequent
outbreak
la
island
previous
unreport
sever
form
infect
caus
chikv
observ
character
occurr
encephalopathi
notabl
elderli
patient
adult
patient
underli
condit
mothertochild
transmiss
viru
also
report
vertic
transmiss
observ
neonat
born
virem
mother
half
infect
neonat
sever
infect
develop
encephalopathi
common
manifest
studi
pathophysiolog
chikungunya
develop
mous
model
chikv
infect
show
wherea
wild
type
wt
adult
mice
develop
system
infect
chikv
intraderm
inocul
wt
mous
neonat
suscept
chikv
neonat
diseas
sever
age
depend
contrast
wt
adult
mice
mice
partial
abrog
typei
interferon
ifn
pathway
ifnabr
mice
develop
mild
diseas
close
mimick
benign
human
chikv
infect
contrast
adult
mice
total
abrog
typei
ifn
pathway
ifnabr
mice
develop
sever
infect
mous
model
infect
lead
viremia
chikv
recov
skelet
muscl
joint
skina
tissu
tropism
match
symptom
observ
human
similar
observ
biopsi
sampl
human
patient
adult
ifnabr
mice
neonat
sever
chikv
diseas
associ
high
viral
load
peripher
tissu
dissemin
central
nervou
system
cn
agreement
result
chikv
antichikv
immunoglobulin
ig
detect
cerebrospin
fluid
human
neonat
adult
patient
encephalopathi
date
effect
treatment
chikv
infect
human
polyclon
antibodi
prepar
viroinactiv
hyperimmun
serum
commonli
use
treatment
human
viral
infect
administr
human
ig
west
nile
viru
arboviru
flavivirida
famili
improv
neurolog
virusassoci
diseas
human
passiv
immun
convalesc
serum
anim
infect
alphavirus
protect
effect
anim
model
like
futur
expans
area
transmiss
chikv
critic
develop
prophylact
therapeut
strategi
especi
individu
risk
sever
diseas
expos
neonat
infect
adult
underli
condit
show
human
ig
purifi
plasma
sampl
donor
convalesc
phase
chikv
infect
hereaft
refer
chikvig
exhibit
potent
prevent
cur
effect
chikv
infect
mous
model
chikv
chikvig
product
process
use
produc
purifi
polyval
ig
commerci
brand
possibl
use
chikvig
human
prevent
treatment
especi
individu
risk
sever
chikv
diseas
isol
obtain
serum
sampl
male
newborn
chikvassoci
encephalopathi
outbreak
chikv
infect
la
amplifi
cell
titer
viru
stock
determin
vero
cell
plaqu
assay
express
plaqueform
unit
pfu
per
ml
plasma
collect
immunoreact
studi
human
plasma
sampl
collect
etabliss
du
sang
obtain
donor
select
n
p
follow
inclus
criteria
report
clinic
episod
febril
arthralgia
evoc
chikv
infect
outbreak
la
absenc
chronic
joint
muscl
symptom
exclud
patient
chronic
joint
muscl
diseas
least
delay
end
acut
diseas
obtain
sampl
exclus
criteria
request
european
regul
includ
serolog
examin
posit
human
hepat
b
c
virus
human
immunodefici
viru
type
human
cell
leukemia
viru
type
parvoviru
manufactur
chikvig
plasma
sampl
n
p
collect
la
region
etabliss
du
sang
donor
convalesc
phase
chikv
infect
inclus
criteria
use
aforement
immunoreact
studi
addit
posit
antichikv
antibodi
enzymelink
immunosorb
assay
elisa
exclus
criteria
sampl
reversetranscriptas
polymeras
chain
reaction
posit
chikv
addit
criteria
aforement
preliminari
studi
ig
purif
normal
human
ig
intraven
administr
highli
purifi
prepar
obtain
plasma
donor
regist
franc
sinc
although
obtain
plasma
donor
continent
franc
chikv
absent
outbreak
la
etabliss
du
sang
implement
measur
prevent
chikv
transmiss
transfus
continent
franc
symptomat
travel
return
area
chikv
circul
exclud
donat
week
exhibit
immunoreact
chikv
iggelisa
neutral
assay
chikvig
purifi
manufactur
process
pool
plasma
sampl
donor
vaccin
chikv
plasma
fraction
use
laboratoir
du
fractionn
et
de
biotechnolog
manufactur
plasmaderiv
therapeut
product
includ
human
ig
coagul
factor
brief
chikvig
prepar
plasma
fraction
purif
step
includ
filtrat
purif
process
result
human
igg
prepar
purifi
elisa
viru
neutral
assay
plasma
sampl
test
antibodi
specif
chikv
igg
sandwich
method
describ
elsewher
plasma
sampl
test
parallel
chikv
antigen
control
ie
mockinfect
vero
cell
result
consid
posit
optic
densiti
od
ratio
od
chikv
antigen
divid
od
control
antigen
chikv
neutral
antibodi
titer
determin
use
plaquereduct
assay
express
highest
dilut
induc
least
plaqu
reduct
mous
experi
ifnabr
mice
provid
f
tangi
aguet
mice
obtain
charl
river
laboratori
franc
mice
handl
accord
institut
pasteur
guidelin
anim
husbandri
kept
level
isol
mice
inocul
intraderm
rout
ventral
thorax
ml
adult
mice
ml
neonat
viral
suspens
dilut
phosphatebuff
salin
pb
passiv
transfer
human
immun
plasma
b
c
chikvig
adult
mice
mous
neonat
intraperiton
inject
ml
ml
respect
indic
dose
immedi
differ
time
chikv
inocul
maxim
practic
dose
mg
kg
adult
mice
mgkg
mous
neonat
differ
outcom
assess
compar
kaplanmei
surviv
curv
use
log
rank
test
determin
viral
load
tissu
serum
sampl
tissu
sampl
homogen
viru
titer
determin
vero
cell
tissu
cytopath
infecti
dose
viral
titer
tissu
serum
sampl
express
respect
first
step
presenc
antichikv
ig
assess
regular
blood
donor
la
report
histori
clinic
manifest
evoc
chikv
infect
outbreak
la
plasma
sampl
collect
septemb
octob
delay
clinic
episod
donat
least
month
addit
mandatori
viral
screen
see
method
plasma
sampl
control
neg
chikv
rna
reversetranscriptas
polymeras
chain
reaction
subgroup
donor
antichikvig
detect
sandwich
elisa
time
plasma
sampl
obtain
plasma
sampl
posit
elisa
display
vitro
neutral
activ
titer
wherea
display
high
neutral
titer
exhibit
neutral
activ
figur
determin
whether
elisa
neutral
titer
correl
randomli
select
sampl
assay
elisa
titer
plasma
sampl
correl
neutral
titer
figur
second
step
select
blood
donor
p
passiv
administr
chikvig
ifnabr
adult
mice
infect
intraderm
rout
pfu
chikv
antibodi
administr
singl
dose
via
intraperiton
rout
immedi
chikv
inject
data
correspond
mice
per
condit
mean
statist
differ
signific
c
passiv
administr
differ
amount
chikvig
ifnabr
adult
mice
infect
intraderm
rout
p
pfu
chikv
nondilut
chikvig
mg
mgkg
dilut
chikvig
mg
mgkg
mg
mgkg
administ
singl
dose
via
intraperiton
rout
immedi
chikv
inject
data
correspond
least
mice
per
condit
statist
differ
comparison
pb
control
follow
chikvig
mg
chikvig
chikvig
viral
titer
p
p
tissu
serum
sampl
mice
inocul
pfu
chikv
via
intraderm
rout
inject
pb
normal
igg
chikvig
mice
sacrif
indic
time
amount
infecti
viru
serum
tissu
sampl
quantifi
tissu
cytopath
infecti
dose
data
point
repres
arithmet
deviat
least
mice
broken
line
indic
detect
threshold
mean
standard
port
clinic
episod
chikv
infect
confirm
serolog
examin
posit
chikv
human
plasma
sampl
obtain
donor
use
manufactur
chikvig
describ
method
purifi
ig
obtain
accord
valid
process
use
produc
commerci
avail
human
polyval
ig
intraven
exhibit
immunoreact
elisa
neutral
assay
wherea
use
neg
control
exhibit
immunoreact
chikv
tabl
adult
mice
test
protect
confer
human
immun
plasma
sampl
chikv
infect
first
evalu
efficaci
prevent
fatal
infect
ifnabr
adult
mice
human
plasma
sampl
select
chose
sampl
differ
immunoreact
pattern
chikv
plasma
sampl
nonimmun
control
human
sampl
devoid
antichikv
immunoreact
elisa
neutral
assay
plasma
sampl
b
sampl
donor
convalesc
phase
chikv
infect
high
elisa
titer
low
neutral
activ
plasma
sampl
c
sampl
exhibit
low
elisa
titer
high
neutral
activ
tabl
first
evalu
innocu
plasma
sampl
inject
mice
intraperiton
ml
nonimmun
immun
plasma
sampl
b
c
mice
remain
aliv
healthi
data
shown
inject
ifna
br
adult
mice
lethal
dose
chikv
pfu
intraderm
singl
dose
ml
plasma
intraperiton
rout
immun
plasma
high
neutral
activ
c
low
neutral
activ
b
complet
protect
ifnabr
adult
mice
lethal
dose
chikv
figur
contrast
administr
nonimmun
plasma
provid
protect
figur
data
indic
passiv
transfer
human
immun
plasma
sampl
highli
permiss
mice
protect
chikv
infect
test
protect
confer
chikvig
ifnabr
adult
mice
inject
ml
mg
chikvig
alon
remain
aliv
healthi
data
shown
observ
human
immun
plasma
inject
ml
mg
mgkg
chikvig
mice
simultan
inocul
lethal
dose
chikv
pfu
protect
lethal
infect
wherea
inject
dose
effect
figur
assess
effect
chikvig
infect
fold
higher
inoculum
chikv
ie
pfu
observ
dose
chikvig
protect
mice
infect
pfu
still
protect
anim
higher
dose
viru
includ
highest
dose
pfu
figur
investig
effect
lower
dose
chikvig
chikv
infect
inject
undilut
chikvig
mg
mgkg
complet
protect
mice
infect
inject
lower
dose
mg
mgkg
protect
mice
wherea
treatment
lower
dose
less
effect
figur
evalu
effect
chikvig
viral
amplif
dissemin
tissu
determin
viral
load
tissu
liver
skelet
muscl
cn
serum
sampl
ifna
br
mice
infect
pfu
chikv
inject
chikvig
pb
day
infect
treatment
chikvig
result
inhibit
viral
amplif
tissu
prevent
viremia
figur
contrast
treatment
alter
viral
propag
mice
high
level
infecti
viru
recov
tissu
serum
sampl
day
infect
high
level
observ
mice
receiv
pb
mice
dead
day
infect
prophylaxi
studi
chikvig
wt
mous
neonat
assess
protect
efficaci
passiv
immunotherapi
chikv
infect
mous
neonat
determin
efficaci
immun
human
plasma
chikvig
prevent
chikv
fatal
infect
mous
neonat
similar
find
ifnabr
adult
mice
intraperiton
inject
ml
nonimmun
human
plasma
immun
plasma
b
well
chikvig
mg
mgkg
mous
neonat
toxic
effect
data
shown
infect
neonat
treat
singl
dose
immun
plasma
b
chikvig
surviv
wherea
mous
neonat
treat
pb
nonimmun
plasma
inocul
intraderm
lethal
dose
chikv
pfu
die
within
day
infect
figur
assess
effect
lower
dose
chikvig
chikv
infect
neonat
treatment
singl
dose
mg
dilut
mgkg
chikvig
complet
protect
infect
figur
treatment
lower
dose
less
effect
although
inject
mg
dilut
mgkg
chikvig
protect
mous
neonat
also
evalu
effect
chikvig
viral
dissemin
tissu
liver
muscl
brain
serum
mous
neonat
infect
pfu
chikv
treatment
chikvig
pb
day
infect
tissu
serum
sampl
obtain
mous
neonat
treat
chikvig
demonstr
littl
detect
infecti
viru
day
day
infect
wherea
tissu
serum
sampl
mice
treat
exhibit
high
viral
load
day
infect
maintain
muscl
day
infect
figur
therapeut
effect
chikvig
adult
neonat
mice
lack
specif
treatment
chikv
infect
avail
date
evalu
therapeut
efficaci
chikvig
ifnabr
adult
mice
wt
mous
neonat
adult
mice
mous
neonat
inocul
pfu
pfu
chikv
respect
time
infect
receiv
singl
dose
mg
mg
respect
chikvig
hour
infect
latter
time
omit
ifnabr
adult
mice
mean
surviv
time
day
contrast
pb
chikvig
inject
hour
infect
therapeut
effect
ifnabr
adult
mice
wt
mous
neonat
administr
chikvig
hour
infect
protect
least
mice
figur
treatment
mous
neonat
hour
infect
signific
effect
mortal
mean
surviv
time
chikv
recent
reemerg
arboviru
high
epidem
potenti
fear
pandem
chikv
infect
aris
statist
differ
comparison
phosphatebuff
salin
pb
control
follow
human
plasma
normal
ig
p
human
plasma
b
chikvig
b
passiv
administr
p
differ
amount
chikvig
mice
infect
intraderm
rout
pfu
chikv
nondilut
mg
dilut
chikvig
administr
singl
dose
via
intraperiton
rout
immedi
chikv
inject
data
correspond
least
mice
per
condit
statist
differ
comparison
pb
p
control
mice
treat
chikvig
mg
chikvig
c
viral
titer
tissu
serum
sampl
mice
inocul
pfu
chikv
via
intraderm
rout
inject
pb
normal
ig
chikvig
mice
sacrif
indic
time
amount
infecti
viru
serum
tissu
sampl
quantifi
tissu
cytopath
infecti
dose
data
point
repres
arithmet
deviat
least
mice
broken
line
mean
standard
indic
detect
threshold
possibl
dissemin
rapid
longdist
travel
transmiss
urban
mosquito
vector
human
chikv
produc
sudden
debilit
diseas
incapacit
joint
symptom
moreov
chikv
infect
caus
neuropatholog
particularli
elderli
person
neonat
fatal
patient
current
neither
specif
treatment
vaccin
avail
chikv
infect
context
develop
prophylact
therapeut
strategi
chikv
infect
prioriti
cours
chikv
infect
human
antibodi
respons
develop
earli
stage
persist
time
fulli
establish
followup
healthi
volunt
vaccin
attenu
chikv
strain
provid
evid
persist
signific
antibodi
vitro
neutral
activ
month
present
studi
provid
evid
similar
observ
individu
vaccin
attenu
chikv
strain
natur
infect
individu
still
circul
neutral
antibodi
month
acut
chikv
infect
studi
detect
rate
antichikv
antibodi
elisa
donor
result
clinic
criteria
use
select
donor
immunoreact
studi
thu
context
high
preval
chikv
infect
eg
popul
select
plasma
donor
earli
postepidem
period
purifi
antichikvig
exhibit
vitro
vivo
neutral
activ
obtain
appli
classic
procedur
use
produc
purifi
polyval
ig
plasma
sampl
donor
select
basi
clinic
criteria
approach
demonstr
possibl
easili
recruit
donor
produc
massiv
amount
chikvig
context
vast
epidem
protect
efficaci
ig
alphaviru
infect
previous
demonstr
mice
evalu
efficaci
preand
postexposur
protect
confer
chikvig
immunocompromis
adult
mice
immunocompet
mous
neonat
mous
model
chikv
infect
exhibit
featur
character
sever
human
chikv
infect
model
singl
dose
chikv
immun
human
plasma
chikvig
inhibit
viral
dissemin
abrog
lethal
associ
chikv
administ
least
h
infect
level
protect
correl
amount
antibodi
transfer
fact
dose
chikvig
protect
anim
higher
adult
mice
mgkg
mous
neonat
mgkg
like
result
higher
suscept
ifnabr
mous
model
inde
wt
mous
neonat
pfu
pfu
adult
ifnabr
mice
mean
surviv
time
shorter
adult
ifnabr
mice
infect
mous
neonat
nevertheless
total
protect
obtain
regardless
mous
ifnabr
statu
age
anim
moreov
chikvig
administr
complet
abolish
viral
dissemin
serum
brain
strongli
allevi
liver
muscl
infect
noteworthi
dose
chikvig
complet
inhibit
viral
replic
muscl
mous
neonat
day
infect
although
dose
abolish
muscl
infect
ifnabr
mice
inde
previous
shown
intraderm
inject
chikv
detect
first
liver
blood
reach
peripher
target
tissu
muscl
joint
skin
present
studi
found
chikvig
strongli
restrict
liver
infect
viremia
total
block
chikv
dissemin
cn
data
suggest
liver
infect
viremia
preced
viru
spread
cn
control
liver
infect
viremia
antichikv
antibodi
suffici
prevent
cn
infect
similarli
shown
administr
antiwest
nile
viru
antibodi
mice
infect
west
nile
viru
prevent
cn
infect
although
human
plasma
sampl
donor
convalesc
phase
infect
chikvig
provid
protect
mice
exhibit
differ
vitro
immunoreact
chikv
inde
human
plasma
b
sampl
chikvig
low
vitro
neutral
activ
wherea
human
plasma
c
sampl
high
vitro
neutral
activ
numer
studi
shown
import
neutral
antibodi
recoveri
protect
viral
infect
addit
neutral
virushost
interact
vivo
protect
antibodi
exert
benefici
effect
via
mechan
antibodydepend
complementmedi
cellular
cytox
attribut
fcgr
engag
studi
antibodi
plasma
b
sampl
low
neutral
activ
confer
protect
chikv
previous
shown
venezuelan
equin
encephalomyel
viru
fcgr
engag
thought
essenti
wide
recogn
passiv
vaccin
appropri
prevent
therapeut
option
mani
viral
infect
human
includ
spread
viral
vertic
transmiss
inde
antibodi
prepar
deriv
vaccin
human
donor
wide
use
prophylaxi
therapi
human
viral
diseas
especi
altern
therapi
avail
particular
hyperimmun
human
igg
use
standard
prevent
therapi
mothertochild
transmiss
hepat
b
varicellazost
virus
polyclon
ig
therapi
also
use
success
parvoviru
enteroviru
west
nile
viru
infect
recent
sever
acut
respiratori
syndrom
coronaviru
infect
treat
convalesc
patient
plasma
contain
antisever
acut
respiratori
syndromecoronaviru
polyclon
antibodi
purif
sever
acut
respiratori
syndromecoronaviru
hyperimmun
ig
pool
convalesc
plasma
also
report
similar
result
report
treat
influenza
infect
human
furthermor
vaccin
develop
frequent
base
previou
report
protect
confer
passiv
immunotherapi
therebi
suggest
vaccin
induc
similar
antibodi
respons
could
effect
altogeth
result
suggest
antivir
prevent
therapi
chikvig
may
constitut
effect
medic
intervent
human
known
exposur
chikv
risk
sever
diseas
prophylaxi
chikvig
could
thu
recommend
especi
birth
neonat
born
virem
mother
well
expos
heavili
immunocompromis
patient
tailormad
immunotherapi
develop
applic
emerg
infecti
agent
neither
treatment
prevent
avail
